Table 5 Patient-derived organotypic brain slices from brain cancer

Establishment of New Model from Primary Tumor

High-Grade:

mGBM⁹², mO⁹²

Low-Grade:

GG⁹², MG⁹², SE⁹²

Metastatic:

NSCLCM⁹²

Establishment Success Rate

High-Grade:

mGBM⁹², mO⁹²

Low-Grade:

GG⁹², MG⁹², SE⁹²

Metastatic:

NSCLCM⁹²

Speed of Model

High-Grade:

mGBM⁹², mO⁹²

Low-Grade:

GG⁹², MG⁹², SE⁹²

Metastatic:

NSCLCM⁹²

High Throughput Capabilities of Model

High-Grade:

mGBM⁹², mO⁹²

Low-Grade:

GG⁹², MG⁹², SE⁹²

Metastatic:

NSCLCM⁹²

Model Genetic or Phenotypic Similarity to Parental Tumor

Low-Grade:

MG⁹²

Model Heterogeneity

Low-Grade:

GG⁹²

Tumor Microenvironment of Model

High-Grade:

mGBM⁹², mO⁹²

Low-Grade:

GG⁹², MG⁹², SE⁹²

Metastatic:

NSCLCM⁹²

Models Ability to Replicate Healthy Tissue Toxicity

High-Grade:

mGBM⁹², mO⁹²

Low-Grade:

GG⁹², MG⁹², SE⁹²

Metastatic:

NSCLCM⁹²

Drug Killing

High-Grade:

mGBM⁹², mO⁹²

Low-Grade:

GG⁹², MG⁹², SE⁹²

Metastatic:

NSCLCM⁹²

Establishment of New Model from Primary Tumor

High-Grade:

mGBM⁹², IS⁹²

Establishment of New Model from Recurrent Tumor

High-Grade:

mGBM⁹²

Establishment Success Rate

High-Grade:

mGBM⁹², IS⁹²

Speed of Model

High-Grade:

mGBM⁹², IS⁹²

High Throughput Capabilities of Model

High-Grade:

mGBM⁹², IS⁹²

Tumor Microenvironment of Model

High-Grade:

mGBM⁹², IS⁹²

Models Ability to Replicate Healthy Tissue Toxicity

High-Grade:

mGBM⁹², IS⁹²

Drug Killing

High-Grade:

mGBM⁹², IS⁹²